RxDoctor Payments Data

Shaunette Phillips

Psychiatric/Mental Health · Wellington, FLNPI 1467090423

Payments from drug & device makers

$1,614in general payments, 2019–2025

Across 51 payments — averaging $31.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$342
  • Boehringer Ingelheim$318
  • AstraZeneca$239
  • Novo Nordisk$159
  • Esperion Therapeutics, Inc.$151
  • Pfizer$71
  • plus $334 from 13 others

What the payments were for

  • Food & beverage$1,57698%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$28,181
Medicare patients
161
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$35,576
XareltoRivaroxaban16$19,551
EliquisApixaban18$13,835
OzempicSemaglutide14$13,005
EntrestoSacubitril/Valsartan13$9,130
Breo ElliptaFluticasone/Vilanterol11$5,263
Advair DiskusFluticasone Propion/Salmeterol17$3,214
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,144
Repaglinide46$1,799
Losartan Potassium191$1,744
SynthroidLevothyroxine Sodium23$1,734
Albuterol Sulfate HfaAlbuterol Sulfate47$1,551
Rosuvastatin Calcium219$1,461
Pioglitazone Hcl112$1,436
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$318$35,57629 claims
PfizerEliquis$71$13,83518 claims
Novo NordiskOzempic$159$13,00514 claims
NovartisEntresto$14$9,13013 claims
GSKBreo Ellipta$20$5,26311 claims
AbbVieSynthroid$60$1,73423 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,212154 claims
Almatica Pharma LLCSertraline Hcl$16$31947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →